Next Article in Journal
Effect of Combining Low Temperature Plasma, Negative Pressure Wound Therapy, and Bone Marrow Mesenchymal Stem Cells on an Acute Skin Wound Healing Mouse Model
Previous Article in Journal
Synthesis, Properties, and Biodegradation of Sequential Poly(Ester Amide)s Containing γ-Aminobutyric Acid
Previous Article in Special Issue
Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both?
Open AccessReview

Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer’s Disease-Related Epileptic Seizures

1
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria 3004, Australia
2
Department of Neurology, Alfred Health, Melbourne, Victoria 3004, Australia
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(10), 3676; https://doi.org/10.3390/ijms21103676
Received: 17 April 2020 / Revised: 20 May 2020 / Accepted: 20 May 2020 / Published: 23 May 2020
Alzheimer’s disease (AD) is the most common form of dementia. An increasing body of evidence describes an elevated incidence of epilepsy in patients with AD, and many transgenic animal models of AD also exhibit seizures and susceptibility to epilepsy. However, the biological mechanisms that underlie the occurrence of seizure or increased susceptibility to seizures in AD is unknown. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that regulates various cellular signaling pathways, and plays a crucial role in the pathogenesis of AD. It has been suggested that GSK-3 might be a key factor that drives epileptogenesis in AD by interacting with the pathological hallmarks of AD, amyloid precursor protein (APP) and tau. Furthermore, seizures may also contribute to the progression of AD through GSK-3. In this way, GSK-3 might be involved in initiating a vicious cycle between AD and seizures. This review aims to summarise the possible role of GSK-3 in the link between AD and seizures. Understanding the role of GSK-3 in AD-associated seizures and epilepsy may help researchers develop new therapeutic approach that can manage seizure and epilepsy in AD patients as well as decelerate the progression of AD. View Full-Text
Keywords: Glycogen synthase kinase 3; Alzheimer’s disease; Epileptic seizures; Hyperphosphorylated tau; Amyloid beta Glycogen synthase kinase 3; Alzheimer’s disease; Epileptic seizures; Hyperphosphorylated tau; Amyloid beta
Show Figures

Figure 1

MDPI and ACS Style

Lin, R.; Jones, N.C.; Kwan, P. Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer’s Disease-Related Epileptic Seizures. Int. J. Mol. Sci. 2020, 21, 3676.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop